



What are they? Rac and Rho are
members of the Ras superfamily of
small GTPases, along with the Rabs,
Rans, Raps, Rals, and so on.
Not to be confused with… Rho, the
transcription terminator in prokaryotes,
or Rho, the subunit of the GABA
receptor, or Rac, the serine/threonine
kinase (also called Akt/PKB).
How were they discovered?  The first
Rho gene was discovered by mistake,
in 1985, by a group trying to clone a
homologue of the α subunit of
human chorionic gonadotropin from
the sea snail Aplysia. Using the
Aplysia Rho sequence, three closely
related mammalian genes were
cloned, now called RhoA, RhoB and
RhoC. Rac was first identified as a
substrate for the C3 transferase that
modifies Rho (although, in fact, the
transferase acts on Rac only
inefficiently). There are three
mammalian types of Rac: Rac1, Rac2
and Rac3 (sometimes called Rac1B).
Do they have any relatives? Lots,
mostly with confusing, unmemorable
or inappropriate names. Several of
them are called Rho (RhoD, RhoE
and RhoG) even though they are no
more closely related to the original
Rho than they are to Rac. What about
RhoF, you may ask? Not yet
discovered. To confuse matters
further, RhoE was re-cloned and
renamed Rnd3 well after its sequence
was first published. Look out for
other family members, such as Cdc42,
TTF and TC10, whose names do not
conform to the R** tag that identifies
other Ras superfamily members.
Why are Rac’n’Rho often mentioned in
the same breath?  Well, Rac’n’Cdc42
doesn’t really trip off the tongue, does
it? It might also have something to do
with the simultaneous publication in
1992 of two Cell papers describing the
functions of Rac and Rho.
Where are they found? Homologues of
Rho and Rac have been identified in
all eukaryotes where anyone has
bothered to look, including yeasts,
worms, insects, plants and mammals
(even camels). But they have not so
far been found in prokaryotes.
What do they do? Rac and Rho
coordinate signal transduction, in
league with Ras. Their initial claim
to fame was that they regulate actin
cytoskeletal organization, but as
soon as biologists started
investigating the contribution of
Rho and/or Rac to their own
favourite assays, it became apparent
that they are involved in vesicle
transport, secretion, phagocytosis,
neurite outgrowth, regulation of
MAP kinase cascades, activation of
transcription factors, apoptosis…
Even the cell cycle community
eventually awakened to their
importance. If you want to avoid
Rac and Rho, stick to prokaryotes.
How do they work? Like all
GTPases, they cycle between a
GTP-bound and a GDP-bound
form. Dogma has it that they are
‘active’ in the GTP-bound form and
‘inactive’ in the GDP-bound form.
Thus, incoming signals should
stimulate an increase in the level of
the GTP-bound form. Although this
was believed to be true for a long
time, it has only recently been
proved formally. The conformation
of Rac and Rho is different when
bound to GTP than when bound to
GDP, and in the GTP-bound
conformation they can interact with
downstream targets and thereby
induce cellular responses.
Who are their known associates? A
multitude of directly interacting
targets have been identified,
including protein kinases (for
example, PAKs and Rho-kinases) and
a whole range of ‘adaptor’ proteins
(for example, POR1 and IQGAP), 
so-called because they bring together
other proteins. Even tubulin can be
made to interact with Rac. What all
these targets do, and how their
activity is altered by Rho and Rac, is
the subject of feverish investigation.
Do we need them? We don’t know
yet. Rac2 knockout mice have no
major defects, but this is not
surprising as Rac2 is specifically
expressed only in haematopoetic
cells. Other Rho and Rac knockout
mice are still in the pipeline.
Do they have commercial potential? A
Rho-kinase inhibitor made headlines
recently, not only for lowering blood
pressure in rats with hypertension
but also for inhibiting invasion of
cancer cells in an animal model.
Activation of Rac can either enhance
or inhibit invasion of cancer cells,
depending on the cell type and the
conditions. So, there is certainly
therapeutic potential in developing
inhibitors and/or activators of Rho
and Rac signalling.
Where can I find out more?
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